Androgen Deprivation Therapy Study

Diabetes Clinical Trial

— ADT  

Official title:

Metabolic and Cardiovascular Complications in Men With Prostate Cancer Undergoing Long-term Androgen Deprivation Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00743327
• Other study ID #: AG0107
• Status: Terminated
• Phase: N/A
• First received: August 26, 2008
• Last updated: August 3, 2012
• Start date: October 2008
• Est. completion date: August 2012

Study information

• Verified date: August 2012
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to examine the link between low testosterone and insulin resistance/diabetes in men undergoing androgen deprivation therapy for prostate cancer. The study will also evaluate other cardiovascular risk factors in these men.

Description:

Lowering of testosterone levels, by medications or surgery (Androgen Deprivation Therapy or ADT), is commonly used in the treatment of prostate cancer. The adverse effects of low testosterone include decreased sex drive, impotence, decreased lean body mass and muscle strength, increased fat mass, decreased quality of life and osteoporosis.

An increase in body fat and decrease in lean body mass may contribute to a decrease in the body's ability to use insulin effectively, leading to insulin resistance and diabetes. Low testosterone levels are also associated with elevated total cholesterol, LDL-cholesterol and triglycerides.

Two groups of non-diabetic men will be studied:

1. Men with known history of prostate cancer who were treated with surgery and/or radiation therapy and are now in remission and not receiving androgen deprivation therapy (non-ADT group).

2. Men with newly diagnosed or known history of prostate cancer who are being advised by their physicians to begin androgen deprivation therapy (ADT group).

The non-ADT group and half of the ADT group will be observed for the development of insulin resistance/diabetes. The other half of the ADT group will receive a diabetes medication called Pioglitazone (Actos) to evaluate any beneficial effects of this medication in the prevention of metabolic dysfunction.

The study will consist of a screening visit and 6 additional study visits throughout one year. Procedures during this study include blood draws, MRI, CT, DEXA scan, insulin clamp procedures, oral glucose tolerance tests, carotid IMT, pulse wave velocity, neuropsychological testing, physical exams and an optional muscle biopsy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men 18 years of age or older with prostate cancer

• Planning to undergo long-term (at least 12 months) ADT

• No known history of diabetes

• No history of ADT

Exclusion Criteria:

• History of ADT or any prior diagnosis of hypogonadism

• Fasting glucose or oral glucose tolerance test results in the diabetic range

• Heart failure (NY classification III or IV)

• Testosterone level less than 250 ng/dl on screening

• History of heart attack or open-heart surgery within the past 6 months

• Use of steroids within the past 3 months, including prednisone, cortisone injections, inhaled steroids (topical steroids are acceptable)

• Use of anabolic steroids (testosterone, DHEA, DHEAS) or any growth promoters (growth hormone itself or analogs of growth hormone) in the past 12 months

• Liver function tests more than 3 times upper normal limits

• Undergoing intermittent ADT

• Uncontrolled thyroid disease (hyper- or hypo-thyroidism)

• Anemia, defined as hematocrit less than 38%

• Not physically capable of completing the tests

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Diabetes
• Hypogonadism
• Inflammation
• Metabolic Syndrome
• Metabolic Syndrome X

Intervention

Drug:
• Pioglitazone
45mg capsule, once daily for 1 year

Locations

Country	Name	City	State
United States	NIA Clinical Research Unit located at Harbor Hospital	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute on Aging (NIA)

Country where clinical trial is conducted

United States, 

References & Publications (5)

Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006 Feb 1;106(3):581-8. — View Citation

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006 Aug 20;24(24):3979-83. — View Citation

Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003 Feb;104(2):195-201. — View Citation

Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20;24(27):4448-56. — View Citation

Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8. Epub 2006 Jan 24. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation for the development of incident diabetes		every 3 months	No
Secondary	Evaluation for other cardiovascular risk factors, markers of inflammation and immunological changes		every 3 months	No